PRESS RELEASE

Diaxonhit and XDx Enter Into a Memorandum of Agreement for the Exclusive License to Market and Perform AlloMap® in Europe

---

Paris, France and Brisbane, California – June 4, 2013 – Diaxonhit, the leading French provider of specialty diagnostic solutions, and XDx, Inc., a U.S. molecular diagnostics company focused on non-invasive tests for transplantation and autoimmune disease, announced today that they have entered into a memorandum of agreement for the exclusive license to market and perform AlloMap Molecular Expression Testing (AlloMap®) in Europe. AlloMap is XDx's flagship diagnostic blood test used by physicians to identify heart transplant recipients who have a low probability of acute cellular rejection. AlloMap has been marketed in the United States since 2005 and is CLIA certified, FDA cleared and obtained CE marking in Europe in 2011.

"*We are very pleased to be the exclusive partner of XDx for marketing AlloMap in Europe. Entering into this exclusive license agreement demonstrates the ability of our new group to successfully carry out its strategy of growth and development. The medical benefits of AlloMap and its success in the United States give us confidence in a rapid adoption in Europe,"* **said Loïc Maurel, CEO of Diaxonhit**.

"*XDx has been a pioneer in high value, high clinical impact molecular diagnostics in the United States. The agreement reached with Diaxonhit will have great benefit for heart transplant recipients throughout Europe. With our European CARGO II validation study completed in 2012, Diaxonhit can build on the tremendous efforts XDx has invested in AlloMap. The strengths of Diaxonhit in the field of transplantation convinced us to grant Diaxonhit an exclusive license,"* **said Peter Maag, CEO of XDx**.

Diaxonhit becomes XDx exclusive partner in Europe

Through its wholly owned subsidiary, InGen, the leader in France for marketing tests related to transplantation, Diaxonhit has a dedicated sales force and access to an extensive commercial network throughout Europe. The group will build on these assets to promote AlloMap.

In Europe, the AlloMap test will be performed centrally by an internationally recognized French laboratory that is a leader in the field of molecular immunology and histocompatibility testing. This approach will enable AlloMap testing to continue with high quality and rapid turnaround time for this important patient segment.

In return for this exclusive European license, XDx will receive an upfront payment upon signature of the definitive agreement, future royalties based on European sales, and milestone payments based on sales performance. These payments will be made in cash and Diaxonhit stock. Payment in stock will be subject to a specific resolution to be submitted to Diaxonhit's shareholders for their approval at the upcoming Annual General Meeting to be held on June 20, 2013.

Substantial progress in the field of heart transplantation

In Europe, more than 2,000 heart transplantations are performed each year. Five countries (France, Germany, Italy, Spain, and UK) perform 70% of these transplants, half of which are conducted in 25 major hospitals(1). The total number of heart transplant patients currently alive in Europe is estimated at more than 15,000.

Heart transplant recipients need to be routinely monitored for acute cellular rejection. Endomyocardial biopsy has been the standard procedure to accomplish this routine surveillance, although this invasive procedure creates some risk of potentially serious adverse complications and rejection grading may be uncertain due to sampling or reader variability. AlloMap rejection surveillance is based on gene expression profiling of peripheral venous blood and is recommended by the International Society for Heart and Lung Transplantation (ISHLT) as a non-invasive method to monitor recipients for heart rejection.

AlloMap, a test successfully adopted in the United States

Developed and marketed since 2005 by XDx in the United States as a CLIA certified test, AlloMap was cleared in 2008 by the U.S. Food and Drug Administration, and has gained acceptance by heart transplantation key opinion leaders to aid in the management of their patients as an alternative surveillance method. 2,000 heart transplants are performed annually in the United States in 120 medical centers, and over 90 centers have used AlloMap. To date, more than 10,000 patients have received the test in the United States. The use of AlloMap has extensive reimbursement coverage by both private and government health insurance.

(1) Source : French Biomedicine Agency

About Diaxonhit

Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in the in-vitro diagnostic field, involved from research to commercialization of specialty diagnostic products.

With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, in-vitro diagnostic kits and advanced equipment. It operates mainly in the fields of transplantation, infectious diseases and autoimmunity, product quality control and rapid tests, including Tetanus Quick Stick ®, a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by Thermo-Fisher/One Lambda, of which it is the largest distributor worldwide.

The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering three main specialty areas: immuno-infection, Alzheimer's disease and cancer.

Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index.

For more information, please visit: http://www.diaxonhit.com.

About XDx

XDx Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high value, non-invasive tests to monitor immune status in transplant recipients and autoimmune disease and potentially improve long-term patient outcomes. The company has commercialized AlloMap Molecular Expression Testing (AlloMap®), which aids physicians in determining the low risk of acute cellular rejection at the time of testing in stable post-cardiac transplant patients. Some of the AlloMap technology developed by XDx may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx also has an active diagnostic development program in system lupus erythematosus, which includes several potential tests to address the high unmet medical need in managing this chronic disease.

For more information, please visit: www.xdx.com.

About AlloMap

AlloMap Molecular Expression Testing is a non-invasive gene expression test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the XDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked in the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, Exonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

CONTACTS

DIAXONHIT
Hervé Duchesne de Lamotte
CFO
+33 1 53 94 52 49
herve.delamotte@diaxonhit.com

XDx, Inc.
Matthew Meyer
Chief Business Officer
+1 415-287-2393
mmeyer@xdx.com

ACTIFIN
Financial Communication
+ 33 1 56 88 11 11
Investors Relations
Alexandre Commerot, acommerot@actifin.fr
Press Relations
Jennifer Jullia, jjullia@actifin.fr

BURNS MCCLELLAN
Media
Justin Jackson
+1 212-213-0006
jjackson@burnsmc.com